Document Classification

Section Type: RESULTS

Text: There was at least 75 % improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52 % of patients who received 45 mg of the interleukin-12 / 23 monoclonal antibody, in 59 % of those who received 90 mg, in 67 % of those who received four weekly 45-mg doses, and in 81 % of those who received four weekly 90-mg doses, as compared with 2 % of those who received placebo (P < 0. 001 for each comparison), and there was at least 90 % improvement in 23 %, 30 %, 44 %, and 52 %, respectively, of patients who received the monoclonal antibody as compared with 2 % of patients who received placebo (P < 0. 001 for each comparison).